SurgeGraph, an AI writing tool designed to help users grow their traffic through humanized, SEO-optimized long-form content ...

Massachusetts, Cambridge Saturday, March 1, 2025, 18:00 Hrs [IST] ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Prothena (NASDAQ:PRTA – Free Report) had its target price upped by Piper Sandler from $94.00 to $110.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have ...

Federal Territory of Kuala Lumpur, Malaysia, February 28, 2025 -- SurgeGraph, an AI writing tool designed to help users grow ...

Performing a detailed error analysis is essential for identifying common failure modes in biometric systems and their impact on security. By addressing these issues through targeted mitigations, the ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

SurgeGraph, an AI writing tool focused on helping users grow their traffic through SEO-optimized long-form content, has ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...